Corvidane

About Corvidane

Corvidane is a biotechnology company focused on developing novel therapeutics to combat heart and liver diseases, specifically targeting atherosclerosis and non-alcoholic fatty liver disease (NAFLD) including its more severe form, non-alcoholic steatohepatitis (NASH). The company leverages the anti-inflammatory and lipid metabolism-improving properties of Omega 7 and Omega 9 fatty acids to create treatments that aim to prevent the two leading causes of death worldwide and the leading cause of liver transplants in the United States. Corvidane's business model involves the research and development of these therapeutics, which are intended to be used as adjuncts to existing treatments like statin therapy. The company primarily serves the healthcare market, including patients suffering from cardiovascular and liver diseases. Revenue is generated through the development and eventual commercialization of these therapeutic products, potentially in partnership with larger pharmaceutical companies.